Sanofi continues to make waves in the bio-tech sector, following a mixed bag of results from various quarters. The company has demonstrated success in COVID-19 vaccine development, notably with better tolerability than rivals. New approvals and data have seen Sanofi expand its
Immunology Footprint. The company has also faced calls for investigation following allegations of using monkeys in lab studies. Mixed results and safety concerns were raised with Sanofi’s eczema drug. The company has been involved in significant deals, including a $1.2B pact for phase 1-stage trispecific and a deal with
Kali Therapeutics for autoimmune treatment. Leadership changes have also taken place in the Specialty Care Business Unit. Amidst these, accusations of 'bribing' providers to boost drug prescriptions led to a lawsuit from Texas. The unusual step back from mRNA seasonal flu vaccine development brought about further interest. While the company has faced controversies, it remains actively invested in the sector.
Sanofi has shown resilience and strategic progress, even if met with challenges at times. The sector watches in anticipation as the company marches onwards.
Sanofi News Analytics from Fri, 06 Jun 2025 07:00:00 GMT to Sun, 19 Apr 2026 01:01:12 GMT -
Rating 6
- Innovation 8
- Information 6
- Rumor -3
